Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients With Advanced Solid Tumors

NCT06779851 is registered in ClinicalTrials.gov with Bright Peak Therapeutics Inc as lead sponsor.

NCT NCT06779851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06779851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Investigation of the Safety, Tolerability and Preliminary Antitumor Activity of BPT567, a Multifunctional PD1-IL18 Immunocytokine in Patients With Advanced Solid Tumors
Lead sponsor
Bright Peak Therapeutics Inc
Phase
Phase 1
Overall status
Terminated
Start date
October 15, 2024
Completion date
March 11, 2026
Enrollment
20 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors